|
1
|
Tentler JJ, Tan AC, Weekes CD, Jimeno A,
Leong S, Pitts TM, Arcaroli JJ, Messersmith WA and Eckhardt SG:
Patient-derived tumour xenografts as models for oncology drug
development. Nat Rev Clin Oncol. 9:338–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pompili L, Porru M, Caruso C, Biroccio A
and Leonetti C: Patient-derived xenografts: A relevant preclinical
model for drug development. J Exp Clin Cancer Res. 35:1892016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fichtner I, Rolff J, Soong R, Hoffmann J,
Hammer S, Sommer A, Becker M and Merk J: Establishment of
patient-derived non-small cell lung cancer xenografts as models for
the identification of predictive biomarkers. Clin Cancer Res.
14:6456–6468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang D, Pham NA, Tong J, Sakashita S, Allo
G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, et al: Molecular
heterogeneity of non-small cell lung carcinoma patient-derived
xenografts closely reflect their primary tumors. Int J Cancer.
140:662–673. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez
J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J and Ling YH:
Response and determinants of sensitivity to paclitaxel in human
non-small cell lung cancer tumors heterotransplanted in nude mice.
Clin Cancer Res. 6:4932–4938. 2000.PubMed/NCBI
|
|
6
|
Daniel VC, Marchionni L, Hierman JS,
Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M,
Peacock CD and Watkins DN: A primary xenograft model of small-cell
lung cancer reveals irreversible changes in gene expression imposed
by culture in vitro. Cancer Res. 69:3364–3373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang XC, Zhang J, Li M, Huang XS, Yang
XN, Zhong WZ, Xie L, Zhang L, Zhou M, Gavine P, et al:
Establishment of patient-derived non-small cell lung cancer
xenograft models with genetic aberrations within EGFR, KRAS and
FGFR1: Useful tools for preclinical studies of targeted therapies.
J Transl Med. 11:1682013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ilie M, Nunes M, Blot L, Hofman V,
Long-Mira E, Butori C, Selva E, Merino-Trigo A, Vénissac N, Mouroux
J, et al: Setting up a wide panel of patient-derived tumor
xenografts of non-small cell lung cancer by improving the
preanalytical steps. Cancer Med. 4:201–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Owonikoko TK, Zhang G, Kim HS, Stinson RM,
Bechara R, Zhang C, Chen Z, Saba NF, Pakkala S, Pillai R, et al:
Patient-derived xenografts faithfully replicated clinical outcome
in a phase II co-clinical trial of arsenic trioxide in relapsed
small cell lung cancer. J Transl Med. 14:1112016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nukatsuka M, Saito H, Nakagawa F,
Tsujimoto H, Sakamoto K, Tsukioka S, Uchida J, Kiniwa M, Kobunai T
and Takechi T: Combination therapy using oral S-1 and targeted
agents against human tumor xenografts in nude mice. Exp Ther Med.
3:755–762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu Y, Wang L, Gu J, Qu K and Wang Y:
Identification of microRNA differentially expressed in three
subtypes of non-small cell lung cancer and in silico functional
analysis. Oncotarget. 8:74554–74566. 2017.PubMed/NCBI
|
|
12
|
Nicholson AG, Chansky K, Crowley J,
Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J and
Rami-Porta R; Staging and Prognostic Factors Committee, ; Advisory
Boards, and Participating Institutions, ; Staging and Prognostic
Factors Committee Advisory Boards and Participating Institutions, :
The international association for the study of lung cancer lung
cancer staging project: Proposals for the revision of the clinical
and pathologic staging of small cell lung cancer in the forthcoming
Eighth edition of the TNM classification for lung cancer. J Thorac
Oncol. 11:300–311. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Johnson JR, Cohen M, Sridhara R, Chen YF,
Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, et
al: Approval summary for erlotinib for treatment of patients with
locally advanced or metastatic non-small cell lung cancer after
failure of at least one prior chemotherapy regimen. Clin Cancer
Res. 11:6414–6421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sequist LV, Martins RG, Spigel D, Grunberg
SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky
A, et al: First-line gefitinib in patients with advanced
non-small-cell lung cancer harboring somatic EGFR mutations. J Clin
Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dungo RT and Keating GM: Afatinib: First
global approval. Drugs. 73:1503–1515. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Malik SM, Maher VE, Bijwaard KE, Becker
RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, et al:
U.S. food and drug administration approval: Crizotinib for
treatment of advanced or metastatic non-small cell lung cancer that
is anaplastic lymphoma kinase positive. Clin Cancer Res.
20:2029–2034. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim DW, Mehra R, Tan DS, Felip E, Chow LQ,
Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, et al:
Activity and safety of ceritinib in patients with ALK-rearranged
non-small-cell lung cancer (ASCEND-1): Updated results from the
multicentre, open-label, phase 1 trial. Lancet Oncol. 17:452–463.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song Z, Wang M and Zhang A: Alectinib: A
novel second generation anaplastic lymphoma kinase (ALK) inhibitor
for overcoming clinically-acquired resistance. Acta Pharm Sin B.
5:34–37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hazarika M, White RM, Johnson JR and
Pazdur R: FDA drug approval summaries: Pemetrexed (Alimta).
Oncologist. 9:482–488. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cohen MH, Gootenberg J, Keegan P and
Pazdur R: FDA drug approval summary: Bevacizumab (Avastin) plus
Carboplatin and Paclitaxel as first-line treatment of
advanced/metastatic recurrent nonsquamous non-small cell lung
cancer. Oncologist. 12:713–718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salgia R, Stille JR, Weaver RW, McCleod M,
Hamid O, Polzer J, Roberson S, Flynt A and Spigel DR: A randomized
phase II study of LY2510924 and carboplatin/etoposide versus
carboplatin/etoposide in extensive-disease small cell lung cancer.
Lung Cancer. 105:7–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
Squamous-cell Non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y, Riley DJ, Chen PL and Lee WH: HEC,
a novel nuclear protein rich in leucine heptad repeats specifically
involved in mitosis. Mol Cell Biol. 17:6049–6056. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ferretti C, Totta P, Fiore M, Mattiuzzo M,
Schillaci T, Ricordy R, Di Leonardo A and Degrassi F: Expression of
the kinetochore protein Hec1 during the cell cycle in normal and
cancer cells and its regulation by the pRb pathway. Cell Cycle.
9:4174–4182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Makita Y, Murata S, Katou Y, Kikuchi K,
Uejima H, Teratani M, Hoashi Y, Kenjo E, Matsumoto S, Nogami M, et
al: Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model
mice of hepatocellular carcinoma. Biochem Biophys Res Commun.
493:800–806. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frank-Kamenetsky M, Grefhorst A, Anderson
NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R,
Fan Y, et al: Therapeutic RNAi targeting PCSK9 acutely lowers
plasma cholesterol in rodents and LDL cholesterol in nonhuman
primates. Proc Natl Acad Sci USA. 105:pp. 11915–11920. 2008;
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hoashi Y: Cationic Lipid Patent
WO2016021683 A1. August 6–2015, issued February 11, 2016.
|
|
29
|
Heyes J, Palmer L, Bremner K and
MacLachlan I: Cationic lipid saturation influences intracellular
delivery of encapsulated nucleic acids. J Control Release.
107:276–287. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sato T, Stange DE, Ferrante M, Vries RG,
Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J,
Siersema PD and Clevers H: Long-term expansion of epithelial
organoids from human colon, adenoma, adenocarcinoma, and Barrett's
epithelium. Gastroenterology. 141:1762–1772. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schneeberger VE, Allaj V, Gardner EE,
Poirier JT and Rudin CM: Quantitation of murine stroma and
selective purification of the human tumor component of
patient-derived xenografts for genomic analysis. PLoS One.
11:e01605872016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Taromi S, Kayser G, Catusse J, von
Elverfeldt D, Reichardt W, Braun F, Weber WA, Zeiser R and Burger
M: CXCR4 antagonists suppress small cell lung cancer progression.
Oncotarget. 7:85185–85195. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R,
Lau J, Chen PL and Lee WH: Small molecule targeting the Hec1/Nek2
mitotic pathway suppresses tumor cell growth in culture and in
animal. Cancer Res. 68:8393–8399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo
B, Chien R, Wang YV, Tsai CY, Wu G, et al: Novel small molecules
disrupting Hec1/Nek2 interaction ablate tumor progression by
triggering Nek2 degradation through a death-trap mechanism.
Oncogene. 34:1220–1230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pollack VA, Savage DM, Baker DA,
Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR,
Smolarek TA, Davis JA, et al: Inhibition of epidermal growth factor
receptor-associated tyrosine phosphorylation in human carcinomas
with CP-358,774: Dynamics of receptor inhibition in situ and
antitumor effects in athymic mice. J Pharmacol Exp Ther.
291:739–748. 1999.PubMed/NCBI
|
|
36
|
Pao W, Wang TY, Riely GJ, Miller VA, Pan
Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ekert JE, Johnson K, Strake B, Pardinas J,
Jarantow S, Perkinson R and Colter DC: Three-dimensional lung tumor
microenvironment modulates therapeutic compound responsiveness in
vitro-implication for drug development. PLoS One. 9:e922482014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Friedrich J, Seidel C, Ebner R and
Kunz-Schughart LA: Spheroid-based drug screen: Considerations and
practical approach. Nat Protoc. 4:309–324. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Perche F and Torchilin VP: Cancer cell
spheroids as a model to evaluate chemotherapy protocols. Cancer
Biol Ther. 13:1205–1213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Endo H, Okami J, Okuyama H, Kumagai T,
Uchida J, Kondo J, Takehara T, Nishizawa Y, Imamura F, Higashiyama
M and Inoue M: Spheroid culture of primary lung cancer cells with
neuregulin 1/HER3 pathway activation. J Thorac Oncol. 8:131–139.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Onion D, Argent RH, Reece-Smith AM, Craze
ML, Pineda RG, Clarke PA, Ratan HL, Parsons SL, Lobo DN, Duffy JP,
et al: 3-Dimensional patient-derived lung cancer assays reveal
resistance to Standards-of-Care promoted by stromal cells but
sensitivity to histone deacetylase inhibitors. Mol Cancer Ther.
15:753–763. 2016. View Article : Google Scholar : PubMed/NCBI
|
